International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.

Oncology pharmacists, pharmacy technicians and assistants are key members of the multidisciplinary health care team (MHT) caring for patients receiving immunotherapy with immune checkpoint inhibitors. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on the role of oncology pharmacy practitioners in caring for patients receiving immune checkpoint inhibitors.Four key recommendations were identified: 1) participation as an integrated, collaborative member of the MHT;2) provision of education and training for patients, students, residents, fellows and other members of the MHT;3) involvement in clinical governance to optimise the use of immune checkpoint inhibitors and4) involvement in research and development in the field of immunotherapy.In summary, oncology pharmacy practitioners play essential roles within the MHT in caring for patients receiving immune checkpoint inhibitors.

International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care.

The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.

The potential competency outcome of vigorous brain training game in the elderly: A systematic review.

Background and Aims: The potential outcomes of vigorous brain training game in the elderly is questionable. Methods: A systematic review of studies reporting the outcomes of brain training game under the PRISMA guideline was conducted using the PubMed database (1997-2022). The selection criteria were clinical studies published in English language. Results: A total of 174 articles were identified by searching keywords. However, after screening the relation of the topic and methodology, 21 articles were included. The results of all studies showed positive outcomes after using the brain training game. Variation in the measurement tools were observed. Conclusion: The brain training game showed a positive effect on the brain function. However, the confirmation studies with large populations and standard measurement tools are required for more validated results.

Genetic screening to avoid adverse drug reactions from medication use and approach patients' better outcomes: A lesson learn from the report of the Queen Savang Vadhana Memorial Hospital.

Background and Aims: The polymerase chain reaction (PCR) technique is adopted for pharmacogenetic testing and adverse drug reaction (ADR) analysis. Methods: PCR was used for testing of pharmacogenetic markers for HLA and non-HLA polymorphism related to specific drugs. Results: Among 76 cases that underwent genetic screening, 7.7%, 11.1%, and 2.7% of the patients were found to be genetically positive for allopurinol, carbamazepine, and abacavir, respectively. Two cases were genetically positive for interferon, and two cases of extensive metabolizers were positive for clopidogrel. One case of a NAT2 slow acetylator for isoniazid was found. Among the 74 cases with complete outcomes, 39.2% showed improvements and 18.9% reported a deterioration. Although no serious ADR was observed, two HLA-B*5701-negative cases reported ADRs (2.7%). All patients positive for IL28B were improved. One patient receiving clopidogrel showed improvements, but another showed deterioration. Finally, the outcome of slow acetylation NAT2 was worse without ADR. Conclusion: PCR-based pharmacogenetic testing is critical for ADR monitoring in a cost-effective manner.